|
HY-101157-25mg
|
MedChemexpress LLC
|
Propargyl-PEG5-acid [CAS 1245823-51-1]
|
|
Cancer-programmed cell death
|
|
|
HY-101157-5mg
|
MedChemexpress LLC
|
Propargyl-PEG5-acid [CAS 1245823-51-1]
|
|
Cancer-programmed cell death
|
|
|
HY-101157-50mg
|
MedChemexpress LLC
|
Propargyl-PEG5-acid [CAS 1245823-51-1]
|
|
Cancer-programmed cell death
|
|
|
HY-101982-10mg
|
MedChemexpress LLC
|
Lys-SMCC-DM1 [CAS 1281816-04-3]
|
|
Cancer-programmed cell death
|
|
|
HY-101982-5mg
|
MedChemexpress LLC
|
Lys-SMCC-DM1 [CAS 1281816-04-3]
|
|
Cancer-programmed cell death
|
|
|
HY-102001-10mg
|
MedChemexpress LLC
|
Tomaymycin DM [CAS 945490-09-5]
|
|
Cancer-programmed cell death
|
|
|
HY-102001-25mg
|
MedChemexpress LLC
|
Tomaymycin DM [CAS 945490-09-5]
|
|
Cancer-programmed cell death
|
|
|
HY-102001-5mg
|
MedChemexpress LLC
|
Tomaymycin DM [CAS 945490-09-5]
|
|
Cancer-programmed cell death
|
|
|
HY-102001-50mg
|
MedChemexpress LLC
|
Tomaymycin DM [CAS 945490-09-5]
|
|
Cancer-programmed cell death
|
|
|
HY-103347-5mg
|
MedChemexpress LLC
|
M50054 [CAS 54135-60-3]
|
|
COVID-19-immunoregulation
|
|
|
HY-103613-1g
|
MedChemexpress LLC
|
Thalidomide-O-amido-C4-NH2 (TFA) [CAS 1799711-25-3]
|
|
|
|
|
HY-103613-100mg
|
MedChemexpress LLC
|
Thalidomide-O-amido-C4-NH2 (TFA) [CAS 1799711-25-3]
|
|
|
|
|
HY-103613-2g
|
MedChemexpress LLC
|
Thalidomide-O-amido-C4-NH2 (TFA) [CAS 1799711-25-3]
|
|
|
|
|
HY-103613-500mg
|
MedChemexpress LLC
|
Thalidomide-O-amido-C4-NH2 (TFA) [CAS 1799711-25-3]
|
|
|
|
|
HY-103614-1g
|
MedChemexpress LLC
|
Thalidomide-O-amido-C8-NH2 (TFA) [CAS 1950635-16-1]
|
|
|
|
|
HY-103614-100mg
|
MedChemexpress LLC
|
Thalidomide-O-amido-C8-NH2 (TFA) [CAS 1950635-16-1]
|
|
|
|
|
HY-103614-2g
|
MedChemexpress LLC
|
Thalidomide-O-amido-C8-NH2 (TFA) [CAS 1950635-16-1]
|
|
|
|
|
HY-103614-500mg
|
MedChemexpress LLC
|
Thalidomide-O-amido-C8-NH2 (TFA) [CAS 1950635-16-1]
|
|
|
|
|
HY-108379-2mg
|
MedChemexpress LLC
|
Boc-C2-Urea-bis(Boc)-C4-Urea-4-phenylacetic acid [CAS 1610413-97-2]
|
|
Cancer-programmed cell death
|
|
|
HY-108730-1mg
|
MedChemexpress LLC
|
Avelumab [CAS 1537032-82-8]
|
|
Cancer-programmed cell death
|
|
|
HY-108730-10mg
|
MedChemexpress LLC
|
Avelumab [CAS 1537032-82-8]
|
|
Cancer-programmed cell death
|
|
|
HY-108730-25mg
|
MedChemexpress LLC
|
Avelumab [CAS 1537032-82-8]
|
|
Cancer-programmed cell death
|
|
|
HY-108730-5mg
|
MedChemexpress LLC
|
Avelumab [CAS 1537032-82-8]
|
|
Cancer-programmed cell death
|
|
|
HY-108730A-1mg
|
MedChemexpress LLC
|
Avelumab (anti-PD-L1) [CAS 1537032-82-8]
|
|
|
|
|
HY-108730A-10mg
|
MedChemexpress LLC
|
Avelumab (anti-PD-L1) [CAS 1537032-82-8]
|
|
|
|
